Heart failure drug vericiguat faces new test in tricuspid regurgitation patients

NCT ID NCT07668739

Not yet recruiting Disease control Sponsor: Daejeon St. Mary's hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug vericiguat can improve right heart function and reduce tricuspid regurgitation in 100 adults with heart failure and reduced pumping ability. Participants take vericiguat daily for 9 months, with regular heart scans and walking tests to measure effects. The goal is to see if it lowers hospitalizations and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vericiguat
What this could lead to: If it works, this could provide a new treatment option for heart failure patients with severe tricuspid regurgitation, potentially reducing hospitalizations and improving quality of life.
What could go wrong: This is a relatively small phase 4 trial (100 participants) testing a drug already approved for heart failure, so the added benefit for this specific condition may be modest or not confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systolic heart failure tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HFREF TRICUSPID REGURGITATION (TR)

Contacts and locations

Locations

Daejeon St.Mary's Hospital

Daejeon, 34943, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.